Opportunity Overview
American Healthcare Capital is proud to be the exclusive representative of Project Prism, an opportunity to acquire a U.S.-based medical imaging software company with an FDA-cleared, patented software platform that enhances how radiologists and healthcare professionals visualize, segment, measure, and document lesions within existing imaging workflows. The Company is pursuing a sale of 100% of the business to a strategic acquirer that can embed the technology into a broader installed base of medical imaging systems, including MRI, X-ray, ultrasound, and nuclear imaging, and integrate with PACS, enterprise imaging, and AI orchestration.
Technology Thesis
The core product is best understood as a workflow-enhancing visualization and measurement layer rather than a detection-only algorithm. A trained user identifies a region of interest in a DICOM image, and the platform helps generate a measurable object with dimensions, area, volume, margin information, and colorized visualization. The software especially enhances visualization and lesion detection in dense tissues such as breast, kidney, lung and liver. The system is designed to support radiologist-controlled workflows and does not replace clinical judgment or act as an autonomous diagnostic engine. This product has low adoption friction for hospital customers, making the asset attractive to buyers that already control the viewer, workstation, hardware, or imaging workflow into which the software can be embedded.
Strategic Buyer Rationale
The value of Project Prism is expected to be highest in the hands of a major strategic buyer. The Company is early in commercialization, but its platform can become more valuable when paired with a buyer’s distribution, customer contracts, sales force, regulatory infrastructure, clinical evidence engine, and installed base. A strategic acquirer could package the software into breast imaging workstations, ultrasound systems, enterprise imaging viewers, AI marketplaces, diagnostic displays, structured reporting tools, or cancer imaging suites, thereby converting a standalone product into a differentiated feature of a larger platform.
Market Tailwinds
Radiology AI adoption is increasingly shaped by workflow integration, clinical trust, data capture, and ease of deployment rather than algorithm novelty alone. For example, dense breast notification requirements and the continued need for supplemental imaging create a strong narrative around tools that improve lesion visualization and enhance radiologist confidence. At the same time, hospitals are cautious about adding disconnected applications and favor technologies that can integrate into current image review environments and complement existing detection, density, risk, triage, and reporting solutions.
Competition and Differentiation
The competitive landscape includes ultrasound AI vendors, mammography AI and density/risk tools, CAD and triage algorithms, PACS/viewer modules, medical display companies, and manual measurement workflows. Project Prism should not be a direct substitute for every detection product. It is complementary. Detection tools can suggest where to look, while Project Prism can help clinicians see, segment, measure, compare, and generate data from a selected region of interest. This makes the technology relevant to both AI companies seeking a richer workflow layer and imaging infrastructure buyers seeking a defensible feature set.
Commercial Profile
Financial statements indicate approximately $170,000 of last-twelve-month revenue, a next-twelve-month projection of approximately $1.0 million, and 100% recurring revenue. The Company reports no business or real estate debt. Current revenue should be framed as early validation; the primary acquisition thesis is strategic control of a novel, patented, FDA-cleared technology asset with embedded-platform optionality.
Valuation and Asking Price
The final valuation and transaction terms will be determined through discussions with qualified parties and will ultimately reflect strategic fit, growth opportunities, transaction structure, and overall market interest. The transaction is expected to be structured on a cash-free, debt-free basis and will exclude accounts receivable, excess working capital, cash, personal assets, and any owned real estate unless otherwise negotiated by the parties.
Process Note
Project Prism is intended for strategic acquirers that can accelerate adoption faster than the Company can as a standalone seller. The preferred outcome is a full-company sale. Asking price is listed as To Be Determined, allowing the process to test strategic value and buyer-specific structures, which may include upfront consideration, milestones, earnouts, or other negotiated economics.